Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Use of ModraDoc006/r in Advanced Solid Tumors
NCT03150368Phase 1Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ModraDoc006 in solid tumor (advanced stage), sponsored by Modra Pharmaceuticals. Primary endpoint: Hematological and non-hematological toxicity profile. Started May 2017; status: completed.
02
Drugs
ModraDoc006
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03150368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150368.